Sectors
The cancer therapeutics developer has filed to float on the Nasdaq Global Market, with Taiho Ventures set to achieve an exit.
The Bristol Myers Squibb-backed oncology drug developer ultimately raised nearly $144m in its initial public offering.
Vision Fund and Advance Publications scored exits but the real estate portal operator ended up significantly downsizing its initial public offering.
The central nervous system-focused drug developer has raised approximately $124m so far from investors including 3M.
The Alibaba, SoftBank and Xiaomi-backed mobile charger producer has floated below its range in a $150m initial public offering.
The Novo-backed musculoskeletal disease therapy developer's market capitalisation stood at $1.6bn as of close of trading yesterday.
The Amazon-backed food delivery service raised $2.07bn in its initial public offering only to see its shares fall some 25% on its opening day.
The Seek Group, Laureate Education and BCC-backed online learning platform developer priced its shares at the top of their range.
Novo, Sanofi and Merck & Co all scored exits as the cancer drug developer, which had been spun off by Biox Biosciences, floated in a $101m offering.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
